November 23, 2021 -- Twist Bioscience has entered into an agreement to purchase Abveris, a private in vivo antibody discovery firm, for $190 million.
Abveris offers antibody discovery services using its DiversimAb collection of hyperimmune mouse models, which can be used to develop biologics, according to Twist.